Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma
Main Article Content
Keywords
melanoma, cutaneous melanoma, gene expression test
Abstract
References
molecular assay for cutaneous melanoma. J Am Acad Dermatol.
2017;76(1)114-120.e2
2. Ferris L et al. Real-world performance and utility of a non-invasive
gene expression assay to evaluate melanoma risk in pigmented
lesions. Mel Res. 2018; 28(5):478-482.
3. Hornberger J and Siegel D. Economic analysis of a non-invasive
molecular pathologic assay for pigmented skin lesions. JAMA
Dermatol. 2018; 154(9)1-8.
4. Ferris L et al. Impact on clinical practice of a non-invasive gene
expression melanoma rule-out test: 12 month follow-up of negative
test results and utility data from a large US registry study. Dermatol
Online J. 2019; 25(5):1-8.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.